Based on these susceptibility loci, genetic testing was widely popularized in Europe and North America, and customized prevention or clinical health management was recommended according to the individual testing results, which could provide an opportunity to reduce the breast cancer risk for those BRCA1/2 pathogenic variant carriers. The gene discussed is BRCA1; the disease is breast carcinoma.